In search of Alzheimer’s disease treatment methods: trends of clinical trials
There is a strong necessity to develop new treatments for Alzheimer’s disease (AD) as its frequency is rapidly growing with the ageing population. There were 25 pharmacological agents involved in phase I trials, 52 in phase II, and 28 agents in phase III clinical trials in 2017. More than two third...
Saved in:
| Main Authors: | G. Pakulaitė, V. Regelskytė, E. Audronytė, J. Kuzmickienė, G. Kaubrys |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2018-03-01
|
| Series: | Neurologijos seminarai |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27849 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review
by: Eliasz Engelhardt, et al.
Published: (2024-12-01) -
Deletion of Murine APP Aggravates Tau and Amyloid Pathologies in the 5xFADXTg30 Alzheimer’s Disease Model
by: Kunie Ando, et al.
Published: (2025-01-01) -
Analysis of cognitive status of Alzheimer’s disease’s subjects and its association with biomarkers (amyloid beta and tau proteins) using NACC data
by: Vaghawan Prasad Ojha, et al.
Published: (2025-04-01) -
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2024-12-01) -
Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)